Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
204 hedge funds and large institutions have $2.76B invested in Amicus Therapeutics in 2018 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 78 increasing their positions, 60 reducing their positions, and 27 closing their positions.
422% more call options, than puts
Call options by funds: $52.2M | Put options by funds: $9.99M
30% more repeat investments, than reductions
Existing positions increased: 78 | Existing positions reduced: 60
19% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 27
2% more funds holding
Funds holding: 200 → 204 (+4)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
19.03% less ownership
Funds ownership: 121.1% → 102.07% (-19%)
22% less capital invested
Capital invested by funds: $3.54B → $2.76B (-$774M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MWNA
Marshall Wace North America
New York
|
+$40.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$22.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$21.4M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$19.1M |
| 5 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
+$17.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$74.2M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$57.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$47.9M |
| 4 |
FM
Frazier Management
Seattle,
Washington
|
-$40.6M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$29.5M |
FOLD Hedge Fund Activity: Q3 2018 in Review
204 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2018, worth a combined $2.76B — down 22% from $3.54B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new FOLD positions and 27 closed out — a net gain of 5 holders — while 78 added to existing stakes and 60 trimmed.
The largest buyer was Marshall Wace North America, adding an estimated $40.1M. The largest seller was OrbiMed, cutting an estimated $74.2M.
- 204 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2018, up from 200 in Q2 2018.
- Funds reported $2.76B of Amicus Therapeutics stock for Q3 2018, down 22% quarter-over-quarter.
- 32 funds opened new Amicus Therapeutics positions in Q3 2018 and 27 closed out, a net change of +5 holders.
- The largest Amicus Therapeutics buyer in Q3 2018 was Marshall Wace North America, an estimated $40.1M added.
- The largest Amicus Therapeutics seller in Q3 2018 was OrbiMed, an estimated $74.2M sold.
Based on aggregated 13F filings for Q3 2018.